Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomyEur Urol Oncol 2022 Jan 03;[EPub Ahead of Print], E Laukhtina, F Quhal, K Mori, R Sari Motlagh, P Rajwa, T Yanagisawa, H Mostafaei, F König, A Aydh, B Pradere, D Enikeev, PI Karakiewicz, M Schmidinger, SF Shariat
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.